Drug
Triheptanoin clinical trials
Also written UX007 and Dojolvi.
- studies test it
- 28
- open now
- 1
- in phase 3
- 3
- first study started
- 2009
Keep track of what changes. Save the triheptanoin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
- UX007
- 11
Studies by the year they started
28 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 5
- Phase 2
- 20
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 22
Ultragenyx Pharmaceutical Inc (6) · Institut National de la Santé Et de la Recherche Médicale, France (3) · Juan Pascual (3) · University of Texas Southwestern Medical Center (2) · Rigshospitalet, Denmark (2) · Jerry Vockley, MD, PhD (2) · The University of Queensland (1) · Areeg El-Gharbawy (1)
Studies
Open first, then newest update. How each study uses triheptanoin is read from its arms, and is right about nine times in ten.
Testing it · 28
- Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) DeficiencyRecruitingPhase 1Jirair Krikor BedoyanNCT06340685Written as Triheptanoin
- A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODActive, not recruitingPhase 3Ultragenyx Pharmaceutical IncNCT05933200Written as Triheptanoin
- Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington DiseaseCompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT01882062Written as Triheptanoin 1g/kg/day
- Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)WithdrawnPhase 2Jerry Vockley, MD, PhDNCT06067802Written as Triheptanoin
- Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)WithdrawnPhase 2Jerry Vockley, MD, PhDNCT07097311Written as Triheptanoin
- Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of ChildhoodCompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02408354Written as Triheptanoin
- Triheptanoin in Mc ArdleCompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02919631Written as Triheptanoin
- Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)CompletedPhase 2University of Texas Southwestern Medical CenterNCT03181399Written as Triheptanoin
- The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With GlycogenosesCompletedPhase 2Rigshospitalet, DenmarkNCT03642860Written as Triheptanoin
- Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1DCompletedPhase 2University of Texas Southwestern Medical CenterNCT03301532Written as Triheptanoin
- Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin StudiesCompletedPhase 2Ultragenyx Pharmaceutical IncNCT02214160Written as UX007
- Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of AnaplerosisCompletedPhase 2The University of QueenslandNCT04513002Written as Triheptanoin
- Treatment Development of Triheptanoin (G1D)CompletedPhase 1Juan PascualNCT03041363Written as Triheptanoin
- Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type ICompletedEarly Phase 1Areeg El-GharbawyNCT03665636Written as Triheptanoin
- A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)CompletedPhase 2Ultragenyx Pharmaceutical IncNCT01886378Written as UX007
- An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency SyndromeCompletedPhase 2Adrian LacyNCT02036853Written as Triheptanoin
- Treatment of Mitochondrial Dysfunction in Rett Syndrome With TriheptanoinStatus unknownPhase 2Center for Rare Neurological Diseases, Norcross, GANCT02696044Written as triheptanoin
- Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)CompletedPhase 2Ultragenyx Pharmaceutical IncNCT01993186Written as UX007
- Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)TerminatedPhase 3Ultragenyx Pharmaceutical IncNCT02960217Written as UX007
- Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)TerminatedPhase 2Ultragenyx Pharmaceutical IncNCT02599961Written as UX007
Codes
What other systems call triheptanoin · ClinicalTrials.gg INT005310
- MeSH (NLM) C531010triheptanoinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2P6O7CFW5KTRIHEPTANOINConfirmed FDA, NLM, Wikidata
- RxNorm 1313234Confirmed FDA, Wikidata
- Wikidata Q414576triheptanoinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166587TriheptanoinOne source FDA
- DrugBank DB11677One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531010 | triheptanoin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2P6O7CFW5K | TRIHEPTANOIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1313234 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414576 | triheptanoin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166587 | Triheptanoin | One source FDA |
| DrugBank | DB11677 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.